公开(公告)号：US20240358893A1

公开(公告)日：2024-10-31

申请号：US18769827

申请日：2024-07-11

Applicant: LYRA THERAPEUTICS, INC.

Inventor： Changcheng You ,  Quynh Pham ,  Danny Concagh

IPC: A61L27/34 ,  A61F2/18 ,  A61F2/90 ,  A61K31/58 ,  A61L27/18 ,  A61L27/54 ,  A61L27/56 ,  A61L27/58 ,  A61M25/10 ,  A61M31/00

CPC classification number: A61L27/34 ,  A61F2/186 ,  A61F2/90 ,  A61K31/58 ,  A61L27/18 ,  A61L27/54 ,  A61L27/56 ,  A61L27/58 ,  A61M25/10 ,  A61M31/002 ,  A61F2210/0004 ,  A61F2250/0031 ,  A61F2250/0067 ,  A61L2300/222 ,  A61L2300/41 ,  A61L2300/604 ,  A61L2300/608 ,  A61M2025/105 ,  A61M2210/0681

Abstract: This disclosure describes, inter alia, materials, devices, kits and methods that may be used to treat chronic sinusitis. More specifically, a drug-eluting scaffold is implanted in the middle meatus to treat chronic sinusitis for weeks to months.

公开(公告)号：US20240358887A1

公开(公告)日：2024-10-31

申请号：US18768745

申请日：2024-07-10

Applicant: GROUPE PPD INC.

Inventor： Daniel MORRISSETTE ,  Vincent MORRISSETTE

IPC: A61L27/18 ,  A61L27/44 ,  A61L27/54 ,  A61L27/56

CPC classification number: A61L27/18 ,  A61L27/44 ,  A61L27/54 ,  A61L27/56 ,  A61L2400/08

Abstract: A porous material suitable for implant is disclosed comprising a large plurality of substantially spherical intercalated hollows in a polymer. The hollows are formed by combining the polymer with a fugitive material under heat and pressure and subsequently removing the fugitive material to reveal the hollows. Intercalation can be increased by subjecting the fugitive material to a coalescing compacting process prior to combining the fugitive material with the polymer. The porous material can be combined with a solid material such as a solid polymer to fabricate complex implantable materials with a variety of features.

公开(公告)号：US20240358714A1

公开(公告)日：2024-10-31

申请号：US18402042

申请日：2024-01-02

Applicant: Allergan, Inc.

Inventor： Patrick M. Hughes ,  Jie Shen ,  Michael R. Robinson ,  David F. Woodward ,  Robert M. Burk ,  Hui Liu ,  Jinping Wan ,  Chandrasekar Durairaj ,  Gyorgy F. Ambrus ,  Ke Wu ,  Danny T. Dinh

IPC: A61K31/559 ,  A61F9/00 ,  A61F9/007 ,  A61K9/00 ,  A61K9/14 ,  A61K31/381 ,  A61K47/34 ,  A61L27/18 ,  A61L27/54 ,  A61L27/58

CPC classification number: A61K31/559 ,  A61K9/0051 ,  A61K9/146 ,  A61K31/381 ,  A61K47/34 ,  A61L27/18 ,  A61L27/54 ,  A61L27/58 ,  A61F9/0017 ,  A61F9/00781 ,  A61L2430/16

Abstract: Prostamide-containing biodegradable intraocular implants, prostamide compounds, prostamide-containing pharmaceutical compositions, and methods for making and using such implants and compositions for the immediate and sustained reduction of intraocular pressure and treatment of glaucoma in an eye of a patient are described.

公开(公告)号：US12121442B2

公开(公告)日：2024-10-22

申请号：US16617707

申请日：2018-05-04

Applicant: University College Dublin, National University of Ireland, Dublin

Inventor： Eoin O'Cearbhaill ,  Fergal Coulter

IPC: A61F2/30 ,  A61L27/18 ,  A61L27/20 ,  A61L27/38 ,  A61L27/54 ,  A61L27/56

CPC classification number: A61F2/30756 ,  A61L27/18 ,  A61L27/20 ,  A61L27/3834 ,  A61L27/54 ,  A61L27/56 ,  A61F2002/30766 ,  A61L2300/62 ,  A61L2300/64

Abstract: The invention broadly provides an implantable medical device comprising a liquid rope coil scaffold. The implant may consist essentially of the scaffold, where the scaffold is the implant and pores in the scaffold may incorporates one or more agents (i.e. drugs, growth factors), or the scaffold may comprise only part of the medical device, for example an implant that is partly or fully covered with a layer of the scaffold. The porosity of the scaffold may be tailored to suit the application, for example a porosity that is tailored to hold and release drug or biological molecules in vivo, a porosity to provide a surface roughness that is conducive to promotion of in-vivo bio-integration (for example vascularisation) or prevention of fibrosis, or a porosity that provides structural strength. The scaffold may be essentially tubular, or may be provided as a planar structure, or may be any shape and can be used to coat, fully or partially any shape or size of medical implant.

公开(公告)号：US20240342343A1

公开(公告)日：2024-10-17

申请号：US18682652

申请日：2022-05-18

Applicant: UNIVERSITEIT MAASTRICHT ,  ACADEMISCH ZIEKENHUIS MAASTRICHT

Inventor： Aart Alexander VAN APELDOORN ,  Rick DE VRIES

IPC: A61L27/56 ,  A61L27/16 ,  A61L27/38 ,  A61L27/52 ,  A61L27/54 ,  B32B3/02 ,  B32B3/26 ,  B32B3/30 ,  B32B7/05 ,  B32B27/08 ,  B32B27/30 ,  B32B27/36

CPC classification number: A61L27/56 ,  A61L27/16 ,  A61L27/3804 ,  A61L27/52 ,  A61L27/54 ,  B32B3/02 ,  B32B3/26 ,  B32B3/30 ,  B32B7/05 ,  B32B27/08 ,  B32B27/304 ,  B32B27/36 ,  B29K2995/0056 ,  B32B2250/24 ,  B32B2255/10 ,  B32B2535/00

Abstract: An open type implantable cell delivery device for transplanting cells in a subject, comprising: a bottom film having a surface area with a plurality of pores; a top film having a surface area with a plurality of pores, positioned on top of the bottom film such that the top film substantially covers the bottom film to create an inner space; wherein the bottom film and the top film are formed from a biocompatible biomaterial, and wherein the bottom film comprises a plurality of microwells positioned to face the surface area of the top film with the open sides of said microwells, wherein the pore size of the bottom film and optionally the top film is such that it allows vascularization or vascular ingrowth in the device through the pores.

公开(公告)号：US12115332B2

公开(公告)日：2024-10-15

申请号：US17516179

申请日：2021-11-01

Applicant: Arizona Board of Regents on Behalf of the University of Arizona ,  Procyon Technologies LLC

Inventor： Klearchos Papas

IPC: A61M37/00 ,  A61F2/02 ,  A61L27/52 ,  A61L27/54

CPC classification number: A61M37/0069 ,  A61F2/022 ,  A61L27/52 ,  A61L27/54 ,  A61L2300/62 ,  A61M2202/03 ,  A61M2205/04

Abstract: Embodiments of the present disclosure relate to encapsulation devices, systems and methods of use. In some embodiments, encapsulation devices for housing cells and providing various therapeutic benefits to a patient or host are described. Encapsulation devices include, for example, a matrix or scaffold within a cell-receiving area or void. Encapsulation devices may include channels that are operable to convey fluid to internal areas of devices without restricting vascularization.

公开(公告)号：US12115282B2

公开(公告)日：2024-10-15

申请号：US18063600

申请日：2022-12-08

Applicant: Research Institute at Nationwide Children's

Inventor： Christopher Breuer ,  Robert Strouse ,  Yong Ung-Lee ,  Cameron Best ,  Narutoshi Hibino

IPC: A61L27/38 ,  A61L27/18 ,  A61L27/20 ,  A61L27/24 ,  A61L27/50 ,  A61L27/54 ,  A61L27/58 ,  B33Y10/00 ,  B33Y80/00 ,  D01D5/00

CPC classification number: A61L27/3834 ,  A61L27/18 ,  A61L27/20 ,  A61L27/24 ,  A61L27/507 ,  A61L27/54 ,  A61L27/58 ,  B33Y10/00 ,  B33Y80/00 ,  D01D5/0076 ,  A61L2300/41 ,  A61L2300/414 ,  A61L2300/416 ,  A61L27/18 ,  C08L67/04 ,  A61L27/18 ,  C08L77/00 ,  A61L27/18 ,  C08L85/02

Abstract: It has been established that optimizing cell seeding onto tissue engineering vascular grafts (TEVG) is associated with reduced inflammatory responses and reduced post-operative stenosis of TEVG. Cell seeding increased TEVG patency in a dose dependent manner, and TEVG patency improved when more cells were seeded, however duration of incubation time showed minimal effect on TEVG patency. Methods of engineering patient specific TEVG including optimal numbers of cells to maintain graft patency and reduce post-operative stenosis are provided. Closed, single-use customizable systems for seeding TEVG are also provided. Preferably the systems are custom-designed based on morphology of the patient specific graft, to enhance the efficacy of cell seeding.

公开(公告)号：US12115280B2

公开(公告)日：2024-10-15

申请号：US17127281

申请日：2020-12-18

Applicant: Edwards Lifesciences Corporation

Inventor： Jeffrey S. Dove ,  Tara J. Tod

IPC: A61L27/36 ,  A61L27/50 ,  A61L27/54

CPC classification number: A61L27/3687 ,  A61L27/50 ,  A61L27/54 ,  A61L2430/20 ,  A61L2430/40

Abstract: Methods are provided herein for modifying antigenic carbohydrate epitopes within a xenographic bioprosthetic tissue by oxidation of vicinal diols to form aldehydes or acids and subsequence reductive amination of aldehydes to form stable secondary amines, or amidation or esterification of acids to form stable amides or esters. Advantageously, methods provided herein mitigate the antigenicity of the bioprosthetic tissue while leaving the overall tissue structure substantially undisturbed, and thereby enhance the durability, safety and performance of the bioprosthetic implant.

公开(公告)号：US20240336064A1

公开(公告)日：2024-10-10

申请号：US18742311

申请日：2024-06-13

Applicant: President and Fellows of Harvard College

Inventor： Daniele Foresti ,  Jennifer A. Lewis ,  Armand Kurum

IPC: B41J2/14 ,  A23G1/54 ,  A23P20/20 ,  A23P20/25 ,  A61L27/24 ,  A61L27/38 ,  A61L27/54 ,  B29C64/112 ,  B29C64/209 ,  B33Y10/00 ,  B33Y30/00 ,  B33Y70/00 ,  B41M5/00 ,  C09D11/52

CPC classification number: B41J2/14008 ,  A23G1/54 ,  A23P20/20 ,  A61L27/24 ,  A61L27/3834 ,  A61L27/54 ,  B29C64/112 ,  B29C64/209 ,  B33Y10/00 ,  B33Y30/00 ,  B33Y70/00 ,  B41M5/0023 ,  C09D11/52 ,  A23P2020/253 ,  A23V2002/00

Abstract: A method of acoustophoretic printing comprises generating an acoustic field at a first end of an acoustic chamber fully or partially enclosed by sound-reflecting walls. The acoustic field interacts with the sound-reflecting walls and travels through the acoustic chamber. The acoustic field is enhanced in a chamber outlet at a second end of the acoustic chamber. An ink is delivered into a nozzle positioned within the acoustic chamber. The nozzle has a nozzle opening projecting into the chamber outlet. The ink travels through the nozzle and is exposed to the enhanced acoustic field at the nozzle opening, and a predetermined volume of the ink is ejected from the nozzle opening and out of the acoustic chamber.

公开(公告)号：US12109334B2

公开(公告)日：2024-10-08

申请号：US18159412

申请日：2023-01-25

Applicant: Washington University

Inventor： Matthew R. MacEwan

IPC: A61L27/18 ,  A61F13/02 ,  A61L15/26 ,  A61L15/44 ,  A61L15/64 ,  A61L27/26 ,  A61L27/54 ,  A61L27/58 ,  A61L27/60 ,  A61L31/04 ,  B29C48/18 ,  B32B5/02 ,  B32B5/26 ,  B32B7/02 ,  B32B7/12 ,  D01D5/00 ,  D04H1/728 ,  D04H3/16

CPC classification number: A61L31/04 ,  A61L15/26 ,  A61L15/44 ,  A61L15/64 ,  A61L27/18 ,  A61L27/54 ,  A61L27/58 ,  A61L27/60 ,  B29C48/18 ,  B32B5/022 ,  B32B5/26 ,  B32B7/02 ,  B32B7/12 ,  D01D5/0007 ,  D01D5/0038 ,  D01D5/0061 ,  D01D5/0076 ,  D04H1/728 ,  D04H3/16 ,  A61F13/02 ,  A61L2300/414 ,  A61L2400/12 ,  A61L2400/18 ,  A61L2430/20 ,  A61L2430/32 ,  B32B2250/20 ,  B32B2262/0276 ,  B32B2307/518 ,  B32B2307/54 ,  B32B2307/726 ,  B32B2307/7265 ,  B32B2556/00 ,  D10B2509/00 ,  A61L15/26 ,  C08L67/04 ,  A61L27/18 ,  C08L67/04

Abstract: A three-dimensional electrospun biomedical patch includes a first polymeric scaffold having a first structure of deposited electrospun fibers extending in a plurality of directions in three dimensions to facilitate cellular migration for a first period of time upon application of the biomedical patch to a tissue, wherein the first period of time is less than twelve months, and a second polymeric scaffold having a second structure of deposited electrospun fibers. The second structure of deposited electrospun fibers includes the plurality of deposited electrospun fibers configured to provide structural reinforcement for a second period of time upon application of the three-dimensional electrospun biomedical patch to the tissue wherein the second period of time is less than twelve months. The three-dimensional electrospun biomedical patch is sufficiently pliable and resistant to tearing to enable movement of the three-dimensional electrospun biomedical patch with the tissue.